Unigestion Holding SA Purchases 36,275 Shares of Cencora, Inc. (NYSE:COR)

Unigestion Holding SA raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 31.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 149,989 shares of the company's stock after buying an additional 36,275 shares during the quarter. Cencora accounts for about 1.6% of Unigestion Holding SA's investment portfolio, making the stock its 23rd largest position. Unigestion Holding SA owned about 0.08% of Cencora worth $33,749,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in COR. New Millennium Group LLC acquired a new position in Cencora in the 2nd quarter valued at approximately $26,000. MFA Wealth Advisors LLC bought a new position in Cencora in the second quarter worth $30,000. Concord Wealth Partners bought a new stake in Cencora in the 3rd quarter valued at $30,000. SYSTM Wealth Solutions LLC acquired a new position in shares of Cencora in the 2nd quarter valued at $36,000. Finally, Ashton Thomas Securities LLC bought a new position in shares of Cencora during the 3rd quarter worth about $41,000. 97.52% of the stock is owned by institutional investors.

Cencora Trading Down 2.2 %

NYSE COR traded down $5.14 on Wednesday, reaching $231.87. The company had a trading volume of 1,714,899 shares, compared to its average volume of 1,391,167. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 52 week low of $195.83 and a 52 week high of $253.27. The stock has a market cap of $44.82 billion, a price-to-earnings ratio of 31.55, a PEG ratio of 1.62 and a beta of 0.45. The stock's 50 day moving average is $237.68 and its 200-day moving average is $233.85.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.95%. Cencora's payout ratio is currently 29.29%.

Analysts Set New Price Targets

COR has been the subject of a number of analyst reports. Mizuho began coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. Leerink Partners reduced their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Barclays increased their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Finally, StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $276.80.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. The trade was a 13.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.